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Abstract. CYP2D6 plays a major role in the metabolism of tamoxifen, and polymorphism of P-
glycoprotein has been associated with resistance of many drug therapies. This study investigates the
clinical impact of genetic variants of CYP2D6 and ABCB1 in breast cancer patients treated with
tamoxifen. Blood samples from 95 breast cancer patients treated with tamoxifen were collected and
genotyped for CYP2D6 and ABCB1 variants using allele-specific PCR method. Recurrence risks were
calculated using Kaplan–Meier analysis and compared using the log-rank test. Patients carrying
CYP2D6*10/*10 and heterozygous null allele (IM) showed higher risks of developing recurrence and
metastasis (OR 13.14; 95% CI 1.57–109.94; P=0.004) than patients with CYP2D6*1/*1 and *1/*10
genotypes. Patients with homozygous CC genotypes of ABCB1 C3435T showed a shorter time to
recurrence. Patients who were CYP2D6 IM and homozygous CC genotype of C3435T have statistically
significant higher risks of recurrence (P=0.002). Similarly, median time to recurrence in these patients
was only 12 months (95% CI=0.79–23.2) compared to those without this combination which was
48 months (95% CI=14.7–81.2). Patients with CYP2D6 IM and homozygous CC genotype of ABCB1
C3435T have shorter times to recurrence. The results confirmed the findings of previous studies and
support FDA recommendation to perform pre-genotyping in patients before the choice of therapy is
determined in breast cancer patients.
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INTRODUCTION
Pharmacogenomics is an area with fast-evolving implica-
tion in clinical setting, and thus, its incorporation to pharma-
ceutical care is believed to enhance patient-centred quality
care. The US Food Drug and Administration has encouraged
the practice of pharmacogenetics testing prior to drug therapy
initiation in some clinically important therapeutics, and tamox-
ifen is one of them. Tamoxifen has been widely used as the
standard adjuvant therapy for hormone receptor-positive breast
cancer patients, especially in the high-risk pre- and postmeno-
pausal women. However, 30% to 50% of oestrogen receptor
(ER)-positive breast cancer patients do not respond to tamoxifen
therapy (1–3). Major challenges to effective tamoxifen therapy
include issues of drug resistance and tamoxifen-induced adverse
events. Tamoxifen is metabolized by a number of cytochrome P-
450 enzymes including CYP2D6, CYP3A4 and CYP2C9.
Genetic polymorphisms of CYP2D6 have been reported as the
major cause of variation in the metabolism of tamoxifen that
leads to adverse effects or lack of therapeutic efficacy (4,5).
Genetic variation inCYP2D6 results in different metabolic
phenotypes including extensive (EM), intermediate (IM), ultra-
rapid (UM) and poor metabolizer. CYP2D6*10 is responsible
for the reduced enzyme activity in IMs whereas CYP2D6*4,
CYP2D6*5 and CYP2D6*14 are null alleles which encode no
enzyme at all. UM (CYP2D6*xN) has a duplication or multi-
duplication of functional alleles and leads to increase enzymes
activity (6–8). This variation causes variability in patients’
outcomes because CYP2D6 had been reported to biotransform
tamoxifen into several active metabolites. Studies on the
pharmacokinetics of tamoxifen demonstrated significantly lower
steady-state plasma and serum concentrations of 4-hydroxy-N-
desmethyltamoxifen and 4-hydroxytamoxifen in CYP2D6*10/
*10 than other genotypes (4,9,10).
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Active metabolites from primary and secondary metab-
olism pathways of tamoxifen known as endoxifen (4-hydroxy-
N-desmethyltamoxifen) and 4-hydroxytamoxifen were found
to be 100-fold more potent than tamoxifen (11). A recent
study among the breast cancer patients with CYP2D6*10/*10
in Asians has shown that the steady-state plasma levels of 4-
hydroxytamoxifen and endoxifen were significantly lower,
and these patients have significant shorter median time to
disease progression compared to patients who were wild type
or heterozygote of CYP2D6*1/*10 (4,9,12). Furthermore, co-
administration of selective serotonin reuptake inhibitors in
breast cancer patients who suffer depressive syndrome was
found to reduce the metabolite concentrations and thus affect
the outcomes of tamoxifen therapy (13,14).
ABCB1 is responsible for multidrug resistance, the
principal mechanism by which many patients with cancer
disorders develop resistance to chemotherapeutic drugs. This
gene encodes P-glycoprotein (P-gp) and functions as an
energy-dependent drug efflux pump and transports a variety
of toxins, nutrients, environmental carcinogens and drugs
(15). Over-expression of this protein in breast cancer tumours
was significantly associated with disease relapse and shorter
disease-free survival period (16). This gene was found to be
highly polymorphic and causes susceptibility to various
disease and therapeutic clinical outcomes. A silent mutation
in exon 26 namely C3435T has been reported to be associated
with therapeutic outcomes in breast cancer treatment and
other disease (17–19). Another allele G2677A/T in exon 21
had been shown to be associated with an amino acid change
in Ala893Thr and Ala893Ser. Substitution of these nucleo-
tides results in change of a lipophilic residue to a hydrophilic
one and affects the geometric precision of the interaction site
and the secondary structure (20). Tamoxifen, 4-hydroxyta-
moxifen and endoxifen are known to bind P-gp and are
substrates of P-gp which may acts as a barrier and limits the
accessibility of active metabolites of tamoxifen to various
critical target tissues and the success of tamoxifen therapy
(21,22). P-gp expression was also found to increase from 40–
50% to 60–70% after chemotherapy in breast cancer patients
and resulted in a shorter overall survival in patients (21).
Our earlier studies reported the heterogeneity of
CYP2D6 among the three different ethnic groups in
Malaysia (23–26), but no studies have investigated the
influence of the polymorphism of CYP2D6 and ABCB1 in
tamoxifen therapy among the patients in Malaysia. We
therefore investigated the impact of CYP2D6 and ABCB1
genotypes on the outcomes of tamoxifen therapy in a
cohort of breast cancer patients.
MATERIALS AND METHOD
Subjects
The study was approved by the Medical Research and
Ethics Committee of Ministry of Health Malaysia, institution-
al review board of both Universiti Teknologi MARA and
Universiti Kebangsaan Malaysia Medical Centre. Five milli-
litres of blood samples was collected from breast cancer
patients at Universiti Kebangsaan Malaysia Medical Centre,
Selayang Hospital and Tengku Ampuan Afzan Hospital after
a written informed consent. Patients recruited comprised of
three ethnic groups predominant in Malaysian, namely
Malays, Chinese and Indians. The ethnicities of all subjects
were confirmed by individual screening and verified
against the new National Registry Identification Cards.
Ninety-five breast cancer patients (53 Malays, 36 Chinese
and 6 Indian) were successfully recruited. Status of ER
and progesterone receptor breast cancer tumour was
determined by immunohistochemistry, and patients re-
ceived tamoxifen 20 mg/day.
Sample Preparation and Genotyping
GenomicDNAwas extracted using alkaline lysis method as
described previously (10), and DNAwas stored at −20°C until
analysis. Patients’ samples were genotyped for CYP2D6*xN,
CYP2D6*4 (rs3892097), CYP2D6*5, CYP2D6*10 (rs1065852),
CYP2D6*14 (rs5030862), ABCB1 C3435T (rs1045642) and
G2677A/T (rs2032582). Nested PCR approach was used to
identify variants of CYP2D6. In the first PCR, 0.2 μM of each
primer, fragment A; forward primer—5′ ACCAGGCCCCTC
CACCGG 3′, reverse primer—5′ AATGCGCCACGCT
CACCCATTGG 3′; fragment B: forward primer—5′
ATGGGTGAGCGTGGCGCATTTCC 3′, reverse primer—5′
TGCACTGTTTCCCAGATGGGCTC 3′, 1.0 U of BioTools
Taq (Biotools B&MLabs. S.A) and 100 ng ofDNAwere used to
amplify fragments A and B. Fragment A spanning exon 1 and
2 served as template for CYP2D6*10 while fragment B
spanning exon 3 to 6 served as template for detection of
CYP2D6*4 and CYP2D6*14. The thermocycling conditions
for this PCR were 95°C for 5 min (initial denaturation),
followed by 35 cycles of 94°C for 1 min; 64°C for 30 s; 72°C for
1.5 min and a final extension of 72°C for 5 min. Eight
microlitres of the PCR product was checked on 1% agarose
gel and appropriately diluted product and was used as the
template in the second PCR.
Allele-specific primers were used for detection of variant and
wild-type alleles in amultiplex PCR. The final reactionwas carried
out in a total volumeof 25 μl PCRmix containing dilutedfirst PCR
product (1:100), 0.06 μM of common primer, forward and reverse
primer: CYP2D6*4—5′ TTGGAGTGGGTGGTGGATGGT 3′,
5′ AGCCCGACTCCTCCTTCAG 3′; CYP2D6*10—5′
ATTTGGTAGTGAGGCAGGTAT 3′, 5′ AACGGCACT
CAGGACTAACT 3′; CYP2D6*14—5′ CAGAGAC
GAGGTGGGGCAA 3′, 5′ TTGCTCACGGCTTTGTCCA 3′,
0.4 μM of wild-type primers, forward primer: CYP2D6*4—5′
CGCATCTCCCACCCCCCG 3 ′ , CYP2D6*10—5 ′
GCTGGGCTGCACGCTAAC 3 ′ , CYP2D6*14—5 ′
GCCTTCGCCAACCACTCAG 3′, 0.2 μM of variant primer,
r eve r se pr imer : CYP2D6*4—5 ′ TGGGGCGAA
AGGGGCGTGT 3′, CYP2D6*10—5′ TGGCAGGGGGC
CTGGTTA 3′, CYP2D6*14—5′ CTTCTGCCCATCACC
CATT 3′, 1% of dimethyl sulfoxide (Sigma-Aldrich Co., St.
Louis USA) and 12.5 μl of 1× of GoTaq® Green Master Mix
(Promega Corporation, Madison, USA) for amplification of
CYP2D6*4, CYP2D6*10 and CYP2D6*14. The thermocycling
conditions were 94°C for 5 min (initial denaturation), followed
by 18 cycles of 94°C for 45 s; 56°C for 45 s; 72°C for 1.0 min and
72°C for 5 min (extra elongation). Eight microlitres of the PCR
product was checked on 1.5% agarose gel. The specificity of the
PCR amplification was confirmed using a positive control for
each allele.
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For gene duplication and deletion of CYP2D6,
previously reported methods were used with some modi-
fication (27,28). Amplification reactions were performed
using 1 U Biotools® Taq DNA Polymerase (Biotools
B&M Labs. S.A, Madrid, Spain), 0.2 μM of primers for
duplication and 0.4 μM of primers for deletion with 12 s
denaturing at 94°C and 5 min annealing/extension at 68°C
for 35 cycles and final extension at 72°C for 10 min. All
reactions were performed in a Takara PCR machine
(TP600, Takara Bio Inc., Japan).
Genotyping for ABCB1 C3435T was performed using
previously designed primers (13) with modification for
common reverse primer: 5′ CAAATAAACAGCATGG
GAGCA 3′. Amplification reactions were performed using
12.5 μl of 1× GoTaq® Green Master Mix (Promega Corpo-
ration, Madison, USA), 0.1 μM of forward primer, 0.2 μM of
reverse primer and 0.3 μM of each allele-specific primers
were used. The reaction was split into two tubes for parallel
amplification of wild-type and variant allele. The conditions
for this PCR were 94°C for 5 min (initial denaturation),
followed by 10 cycles of 94°C for 30 s; 61°C for 30 s; 72°C for
20 s; followed by 25 cycles of 94°C for 30 s; 55°C for 30 s and
72°C for 30 s.
The variant and wild-type specific primers of ABCB1
G2667A/T were split into three tubes, and each reaction was
internally controlled for amplification failure. 1× GoTaq®Green
Master Mix (Promega Corporation, Madison, USA), 0.1 μM of
common forward primer: 5′CTATAGGTTCCAGGCTTGCTG
3′, 0.2 μM of common reverse primer: 5′ GGAAGGAAGAA
CAGTGTGAAGAC 3′ and 0.3 μM allele-specific primers: 5′
TGAAAGATAAGAAAGAACTAGAAGGCG 3′, 5′
TGAAAGATAAGAAAGAACTAGAAGGCA 3′, 5′
TGAAAGATAAGAAAGAACTAGAAGGCT 3′ were used
for each allele. Specificity of the primer sets was confirmed using a
positive control for each allele. The PCR conditionswere 80°C for
5 min and 94°C for another 5 min (initial denaturation), followed
by 8 cycles of 94°C for 30 s; 61°C for 45 s; 72°C for 20 s; and
subsequent 25 cycles of 94°C for 45 s; 58°C for 30 s; 72°C for 1min
and 72°C for 5 min. Ten microlitres of the PCR product was
checked on 1.5% agarose gel.
The metabolizer status of CYP2D6 was defined as (1) EM,
with absence of variant alleles; (2) heterozygous intermediate
metabolizer (Het-IM), with presence of one allele of
CYP2D6*10 and (3) IM with homozygous CYP2D6*10 or
having a combined allele of heterozygous null alleles. For
statistical reasons, individuals with duplicated allele without any
null alleles were included in the EM group.
Statistical Analysis
The association of the genetic variants of CYP2D6 and
ABCB1 with recurrence and metastasis of breast cancer was
investigated. Allele frequencies of CYP2D6 and ABCB1 with
their respective Hardy–Weinberg equilibrium were calculat-
ed. The differences in allele frequencies with different
patients’ characteristic were determined using the ϰ2 test or
Fisher’s exact test. Odds ratios and corresponding 95% CI
were calculated for risk estimation and trend of association
between genotypes and recurrence or metastasis. Tukey’s test
was used to determine the combination effects of CYP2D6
and ABCB1 based on the number of risk alleles. Recurrence-
free rate was analysed using Kaplan–Meier methods. The
recurrence-free period was defined as the period between
surgery and initiation of tamoxifen therapy to the recurrence
of breast cancer or metastasis. Statistical significance analysis
of a relationship between outcomes and genetic
polymorphism was assessed by the log-rank test. All P
values were two sided, and values less than 0.05 were
considered statistically significant. Statistical tests were run
using SPSS version 18 on an IBM-compatible computer.
RESULT
Allelic Distribution of CYP2D6 and ABCB1
CYP2D6*4, CYP2D6*xN, CYP2D6*5, CYP2D6*10,
CYP2D6*14 and C3435T, G2677A/T alleles of ABCB1 were
successfully amplified in 95 patients (Table I). Their genotype
frequencies are as shown in Table II. The genotype and allele
frequencies of CYP2D6 in the breast cancer patients were
compared with those among Malaysian healthy populations
and Singapore breast cancer patients (7,10–13). The most
common allele detected was CYP2D6*10; 47.2% patients
were heterozygous and 22.6% were homozygous
CYP2D6*10. The genotypes for both CYP2D6 and ABCB1
were in Hardy–Weinberg equilibrium.
Risk Estimation Between Genotypes of CYP2D6
and ABCB1 Variants
Patients with CYP2D6 IM genotype appeared to be at
higher risk of developing recurrence and metastasis compared
to CYP2D6 EM genotype (OR 13.14; 95% CI 1.54–109.94; P=
0.004; Table III). Carriers of CYP2D6 Het-IM genotype also
showed an increased risk, but the difference was not statistically
significant (OR 2.71; 95% CI 0.28–25.78; P=0.78). On the other
hand, patients with combination of CT and TT genotypes of
ABCB1 C3435T have lower risk to disease relapse but was not
significant (OR 0.46; 95% CI 0.16–1.34; P=0.15). Patients with
genotypes of G/A or G/T and AT of G2677A/T were found to
have higher risk of disease relapse, but no statistically significant
association was observed (OR 1.41; 0.35–5.71; P=0.63).
CYP2D6 and ABCB1 Variants and Onset of Recurrence
and Metastasis
Time to develop recurrence and metastasis was evaluated
using the Kaplan–Meier analysis. The recurrence-free rate was
measured from the date of diagnosis to the date of the first
instance of recurrence and metastasis. Patients carrying
CYP2D6 IM genotypes had significantly shorter recurrence-
free survival compared to patients with CYP2D6 EM and Het-
IM genotypes (log-rank; P=0.031, Fig. 1a). No statistically
significant association was detectable for ABCB1 C3435T (log-
rank; P=0.22, Fig. 1b), but patients with CC genotype have
earlier onset of relapse compared to CT and TT genotypes.
Kaplan–Meier analysis showed a different trend for genotypes
of ABCB1 G2677T compared to C3435T, but it was not
statistically significant (P=0.97, Fig. 1c).
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Association of Genotypes and Patients’ Clinical Outcomes
Patients carrying CC genotype of ABCB1 C3435T were
found to have shorter recurrence-free survival. This genotype
was combined with CYP2D6 IM to investigate the combina-
tion effect on the onset of relapse. Patients were classified
into five groups according to the number of risk alleles (0, 1,
2, 3, 4 risk alleles group; Table III). Patients carrying three
and four risk alleles were found to have higher risk in
developing disease compared with other alleles (OR 9.9; 95%
CI 2.11–46.6; P=0.001). Kaplan–Meier analysis revealed that
patients have shorter recurrence-free survivals (P=0.01,
Fig. 2a) if they have a combination of risk alleles. Time to
recurrence and metastasis were evaluated among relapsing
Table 1. Clinical and Pathological Characteristics of 95 Patients Subgrouped According to CYP2D6 and ABCB1 Alleles
Variant
CYP2D6 ABCB1 C3435T ABCB1 G2677 (A/T)
WT VT P (VT vs. WT) C T P (C vs. T) G A/T P (G vs. A/T)
Characteristic (n=95, alleles=190) P value/OR (95% CI) P value/OR (95% CI) P value/OR (95% CI)
Age at surgery
Median (range), 51 (33–79)
Menopausal status (pre- vs. post-)
Pre- (n=33, alleles=66) 25 41 0.13a 43 23 0.68a 38 28 0.37a
Post- (n=62, alleles=124) 61 63 1.58 (0.86–2.92) 77 47 1.14 (0.61–2.13) 63 61 1.31 (0.71–2.39)
Histology (DIC vs. LIC)
DIC (n=82, alleles=164) 77 87 0.29b 103 61 0.71b 90 74 0.14b
LIC (n=4, alleles=8) 2 6 0.37(0.07–1.92) 6 2 0.56 (0.11–2.88) 2 6 3.65 (0.72–18.62)
Others (n=9, alleles=18)
Tumour grade (2+3 vs. 1)
1 (n=34, alleles=86) 39 47 1.0a 52 34 0.008a, c 45 41 0.84b
2 and 3 (n=52, alleles=104) 47 57 1.01 (0.57–1.79) 68 18 2.47 (1.26–4.86) 56 48 1.06 (0.59–1.88)
Tumour stage (III + IV vs. 0–II)
0–II (n=70, alleles=140) 69 69 0.05a 81 47 0.06a 75 65 0.84a
III and IV (n=25, alleles=50) 17 33 1.94 (0.99–3.81) 39 11 2.05 (0.96–4.39) 26 24 0.94 (0.49–1.79)
ER and/or PR status (Pos vs. Neg)
Pos (n=78, alleles=156) 69 87 0.54a 97 59 0.55a 85 71 0.43a
Neg (n=17, alleles=34) 17 17 1.26 (0.59–2.65) 23 11 0.78 (0.36–1.73) 16 18 1.34 (0.64–2.03)
Patients with C allele of ABCB1 C3435Twere found to have statistically higher odds ratio for tumour grade 2 and 3 compared to tumour grade
1 (OR 2.47; 95% CI 1.26–4.86; P=0.008)
Abbreviations: WT wild type, VT variant, DIC ductal invasive carcinoma, LIC lobular invasive carcinoma, ER oestrogen receptor, PR
progesterone receptor, Pos positive, Neg negative
a ϰ2 test
b Fisher’s exact test
cA significant association
Table II. The CYP2D6 and ABCB1 Allele Frequencies
Polymorphism Allele
Allele frequencies
P value (95% CI)Current study Malaysian populationa Singapore breast cancer patientsb
A (n=95) B (n=429) C (n=165) A vs. B A vs. C
CYP2D6 *1 41.6 51.5 36.7 Refc
*4 2.1 1.6 0.3 1.0 0.5
*5 4.7 1.9 8.0 0.2 0.4
*10 48.9 43.1 51.0 0.3 0.4
*14 1.1 2.0
*xN 1.6 1.9 2.0 1.0 1.0
ABCB1





Abbreviations: A vs. B current study vs. Malaysian population, A vs. C current study vs. Singapore breast cancer patients
a (1) Teh et al. 2001, (2) Ismail et al. 2001 and (3) Ismail et al. 2003
bLim et al. 2011
c CYP2D6*1 was used as the reference
dTeh et al. 2007
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patients with their genotypes (recurrence and metastasis, n=
11; metastasis only, n=6). Median time to develop recurrence
and metastasis in intermediate metabolizers of CYP2D6 and
CC group of ABCB1 C3435T was only 12 months (95% CI=
0.79–23.2, n=3) compared to 48 months (95% CI=14.7–81.2,
n=8) in patients with genotype of CYP2D6 IM or CC group
of ABCB1 C3435T or other genotypes. The difference was
found to be statistically significant (log-rank; P=0.002,
Fig. 2b). A similar trend was observed in patients who have
both recurrence and metastasis (n=11) and those with
metastasis only (n=6), but no statistical significance was
found (Fig. 2c).
DISCUSSION
The clinical benefit of tamoxifen has significantly im-
pacted ER-positive breast cancer patients, but approximately
one third of patients have recurrence within 15 years (29).
Heterogeneity in patients’ responses to tamoxifen among
breast cancer patients is consistently observed across patient
populations where administration of the same dose of this
drug results in a range of outcomes which include adverse
events or therapeutic failure. Many clinical variables have
been associated with drug response such as age, diet,
menopausal status, lifestyle and tumour biology. Important
achievements also have been obtained in optimisation of drug
therapy based on classification of diseases using protein
expression profiles of the breast cancer tumours. However,
the genetic background of a patient with respect to metabo-
lizing enzymes, drug transporters and correlation of patients’
clinical data that determine efficacy and toxicity of the
therapy is still lacking.
Lim et al. demonstrated that patients prescribed with
tamoxifen and carrying CYP2D6*10/*10 genotype have
slower response towards therapy compared patients with
CYP2D6*1/*1 or CYP2D6*1/*10 genotypes (4). Furthermore,
breast cancer patients who received adjuvant tamoxifen
therapy revealed worse therapy outcomes in patients with
Table III. Risk Estimation Between Genotype and Recurrences and Metastasis in Breast Cancer Patients
Variant
Overall No event Event Statistic
No. Percentage No. Percentage No. Percentage OR 95% CI P
CYP2D6
Homo-EM 24 25.3 23 29.5 1 5.9 1.0 (ref)a
Het-IM 38 40.0 34 43.6 4 23.5 2.71 0.28–25.78 0.78b
IM 33 34.7 21 26.9 12 70.6 13.14 1.54–109.94 0.004b, c
ABCB1
C3435T
CC 41 43.2 31 39.7 10 58.8 1.0 (ref)a
CT 38 40.0 32 41.0 6 35.3 0.58 0.19–1.79 0.34d
TT 16 16.8 15 19.3 1 5.9 0.21 0.02–1.76 0.15e
CT and TT combined
CT+TT 54 56.8 47 60.3 7 41.2 0.46 0.16–1.34 0.15d
G2677A/T
GG 32 33.7 29 34.5 3 27.3 1.0 (ref)a
G/(A or T) 37 38.9 32 38.1 5 45.5 1.51 0.33–6.89 0.72e
AT 26 27.4 23 27.4 3 1.2 1.26 0.23–6.84 1.00e
G/(A or T) and AT combined
G/(A or T)+AT 63 66.3 55 65.5 8 72.7 1.41 0.35–5.71 0.63e
No. of risk alleles of CYP2D6 and ABCB1 C3435T
0 6 6.3 6 7.7 0 0
1 15 15.8 15 19.2 0 0
2 28 29.5 26 33.3 2 11.8 1.0 (ref)f
3 30 31.6 20 25.6 10 58.8 6.5 1.28–33.05 0.04b, c
4 16 16.8 11 14.2 5 29.4 5.9 0.99–35.21 0.15b
No. of risk alleles of CYP2D6 and ABCB1 C3435T combined
0 6 6.3 6 7.7 0 0
1+2 43 45.3 41 52.6 2 11.8 1.0 (ref)f
3+4 46 48.4 31 39.7 15 88.2 9.9 2.11–46.6 0.001b, c
No. of risk alleles—patients were classified into five groups according to combination genotypes of CYP2D6 and ABCB1 C3435T (0—Homo-
EM of CYP2D6 and homozygous mutant of ABCB1, 1—Het-IM of CYP2D6 and homozygous mutant of ABCB1 or Homo-EM of CYP2D6
and heterozygous ABCB1, 2—Het-IM ofCYP2D6 and heterozygous of ABCB1, 3—Het-IM of CYP2D6 and homozygous wild type of ABCB1
or IM CYP2D6 and heterozygous of ABCB1, 4—IM of CYP2D6 and homozygous wild type for ABCB1)
Abbreviations: Homo-EM homozygous wild-type allele for *xN, *4, *5, *10, *14, HetIM one allele of *10 and IM homozygous of *10 or having a
combined allele of heterozygous null alleles; ABCB1 C3435T (CC homozygous wild type, CT heterozygous, TT homozygous mutant) and
G2677A/T (GG homozygous wild type, G/(A or T) heterozygous, AT homozygous mutant)




e Fisher exact test
fThe reference category included ≤2 risk alleles
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the CYP2D6*10/*10 genotype and significantly higher inci-
dence of recurrence within 10 years after the operation
(10,12). Among Caucasians, tamoxifen-treated patients
carrying the heterozygous and homozygous CYP2D6*4
had a significantly increased risk of recurrence of breast
cancer, shorter relapse-free periods and worse event-free
survival rates compared with carriers of functional alleles
(30,31). In contrast, two studies from Japan showed that
CYP2D6*10/*10 genotype was unlikely to have any
clinical significance on breast cancer patients receiving
adjuvant tamoxifen (32,33).
Our result are consistent with the hypothesis that the
CYP2D6*10/*10 and heterozygous null alleles metabolize
tamoxifen slower and thus produce less pharmacologically
active tamoxifen metabolites resulting in a higher risk of
recurrence and metastasis. We demonstrated that carrier of
CYP2D6*10/*10 with combination heterozygous null allele
showed higher incidence of developing recurrence and
metastasis than patients with CYP2D6*1/*1 and CYP2D6*1/
*10 (log-rank test; P=0.031). In addition, genetic polymor-
phism of Malays was found to be different from Chinese and
Far Eastern races and their CYP2D6 activity was hypoth-
esised to be intermediate between East Asian and Caucasian
(23). This could explain the discrepancy results between this
study and the study from Japan.
From our study, the CC genotype for ABCB1 C3435T
has a shorter time in developing recurrence and metastasis
although the association was not statistically significant (P=
0.22). Previous studies showed that expression of P-gp protein
level was twofold higher for homozygous CC genotype
compared to TT genotype (34). Thus, the expression of this
genotype would cause lower bioavailability of tamoxifen and
its metabolites in patients. Genotypes of CT, TT and
combination of CT/TT did not show an increased risk in
developing relapse. Homozygous TT genotype is associated
with lower ABCB1 expression and has been correlated with
reduced expression and functional status of P-gp protein
compared to CC genotypes (35). Transportation of tamoxifen
would be slower and benefited patients with TT genotype.
However, accumulation of tamoxifen or active metabolites
after several years would increase chances of cells becoming
resistant towards therapy. In addition, ABCB1 mRNA levels
were higher in high-grade tumours compared to low-grade
tumours and this relationship might be an indicator of
patient’s clinical outcomes (36). Recent studies in non-small
cell lung cancer showed GG and CC genotype of G2677A/T
Fig. 2. Kaplan–Meier probabilities of time to develop recurrence andmetastasis in patients treatedwith tamoxifen. Patients were classified according
to combined genotypes ofCYP2D6 andABCB1. a Patients were classified into five groups (0, 1, 2, 3, 4) based on the number of risk alleles, combined
for 1+2 risk alleles and 3+4 risk alleles; b combined effect ofCYP2D6 andABCB1 C3435T genotypes with time to develop recurrence + metastasis
(combination of CYP2D6 IM+CC genotypes of ABCB1 C3435T vs. without combination—other CYP2D6 and ABCB1 C3435T genotype
combination); c combined effect of CYP2D6 and ABCB1 C3435Twith time to develop recurrence and metastasis + metastasis only
Fig. 1. Kaplan–Meier probabilities of time to develop recurrence and metastasis in patients treated with tamoxifen predicted from CYP2D6
and ABCB1 genotypes: a carrier of CYP2D6, extensive metabolizer (EM), heterozygous intermediate metabolizer and intermediate
metabolizer (IM); b carrier of ABCB1 C3435T, homozygous wild type (CC) vs. heterozygous (CT) and homozygous mutant (TT); c carrier of
ABCB1 G2677A/T, homozygous wild type (GG) vs. heterozygous {G(A or T)} and homozygous mutant (AT)
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and C3435T were associated with a significantly better
response to docetaxel–cisplatin compared with the combined
of heterozygous and homozygous mutant of both gene,
respectively (37).
In this study, we also performed combination analysis of
patients having both CYP2D6 IM and CC genotype of
ABCB1 in patients with relapse. This group was compared
with similar groups of patients but carrying only either
CYP2D6 IM or homozygous wild-type CC or other genotypes
of ABCB1. Patients with combination of these genotypes
have shorter recurrence-free rates (P=0.002). To our knowl-
edge, this is the first study to address the correlation between
CYP2D6 and ABCB1 variant with clinical outcomes among
breast cancer patients treated with tamoxifen.
CONCLUSION
This finding is particularly important in the discovery of
the effectiveness and resistance of tamoxifen therapy among
breast cancer patients. These lines of evidence imply that pre-
genotyping of CYP2D6 intermediate metabolizer and homo-
zygous wild-type C3435T is important before prescribing
tamoxifen. It is thus recommended that clinical pharmacists
should be aware of this and incorporate the practice of
“PharmacoDiagnostics” in the relevant pharmacy practice as
routine when appropriate.
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